Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease
Background and Aims Crohn’s disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD. Methods Patients with CD were rand...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2020, Vol.65 (1), p.150-157 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 157 |
|---|---|
| container_issue | 1 |
| container_start_page | 150 |
| container_title | Digestive diseases and sciences |
| container_volume | 65 |
| creator | Yang, Zhenyu Bu, Chibin Yuan, Wei Shen, Zhaohua Quan, Yongsheng Wu, Shuai Zhu, Changxin Wang, Xiaoyan |
| description | Background and Aims
Crohn’s disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD.
Methods
Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform.
Results
Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258,
p
|
| doi_str_mv | 10.1007/s10620-019-05751-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_infotracmisc_A712935441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712935441</galeid><sourcerecordid>A712935441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-1199f92d6d2f7b612260cfa98b1237b2dfe311a06867e5de213315b5d477c7d13</originalsourceid><addsrcrecordid>eNp9kcFu1DAURSMEokPhB1ggS2zYpPjZiZ2wq6YtVCqwYFhbjvM84yqxBzupNBILfoPf40vwdEoRCCEvbNnnXt-nWxTPgZ4ApfJ1AioYLSm0Ja1lDeXuQbGAWvKS1aJ5WCwoiHwGEEfFk5SuKaWtBPG4OOLAhWykXBRfL9Dogbx3JobOhUmTVdQ-bQftJ3LjNDn3fUgmbJ0hZzi4G4zOr8lqE8O83pBPox4GcuknTJPzSLTvyTIMwb8hHwI5c9ZiRG-Q2BDJMoaN__Hte8oPCXXCp8Ujq4eEz-724-Lzxflq-a68-vj2cnl6VZqqYlMJ0La2Zb3omZWdAMYENVa3TQeMy471FjmApqIREuseGXAOdVf3lZRG9sCPi1cH320MX-YcVY0uGRzykBjmpLKhlFXDG57Rl3-h12GOPqe7pVhT1xm8p9Z6QOW8DVPUZm-qTiWwltdVtf_25B9UXj2OzgSP1uX7PwTsIMhlpBTRqm10o447BVTtK1eHylWuXN1WrnZZ9OIu8dyN2N9LfnWcAX4A0nbfHcbfI_3H9ifnhbYe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2267285548</pqid></control><display><type>article</type><title>Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease</title><source>Springer Online Journals</source><creator>Yang, Zhenyu ; Bu, Chibin ; Yuan, Wei ; Shen, Zhaohua ; Quan, Yongsheng ; Wu, Shuai ; Zhu, Changxin ; Wang, Xiaoyan</creator><creatorcontrib>Yang, Zhenyu ; Bu, Chibin ; Yuan, Wei ; Shen, Zhaohua ; Quan, Yongsheng ; Wu, Shuai ; Zhu, Changxin ; Wang, Xiaoyan</creatorcontrib><description>Background and Aims
Crohn’s disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD.
Methods
Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform.
Results
Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258,
p
< 0.05) and Shannon diversity index (2.05 vs. 3.46,
p
< 0.05). The CD patients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CD patients had lower levels of
Bacteroides
,
Eubacterium
,
faecalibacterium
, and
Roseburia
, and higher levels of
Clostridium
,
Cronobacter
,
Fusobacterium
, and
Streptococcus
.
Conclusions
FMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CD patients.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-019-05751-y</identifier><identifier>PMID: 31367877</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Colonoscopy ; Crohn's disease ; Feces ; Gastroenterology ; Hepatology ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Microbiota ; Microbiota (Symbiotic organisms) ; Oncology ; Original Article ; Transplant Surgery ; Transplants & implants</subject><ispartof>Digestive diseases and sciences, 2020, Vol.65 (1), p.150-157</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-1199f92d6d2f7b612260cfa98b1237b2dfe311a06867e5de213315b5d477c7d13</citedby><cites>FETCH-LOGICAL-c442t-1199f92d6d2f7b612260cfa98b1237b2dfe311a06867e5de213315b5d477c7d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-019-05751-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-019-05751-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31367877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Zhenyu</creatorcontrib><creatorcontrib>Bu, Chibin</creatorcontrib><creatorcontrib>Yuan, Wei</creatorcontrib><creatorcontrib>Shen, Zhaohua</creatorcontrib><creatorcontrib>Quan, Yongsheng</creatorcontrib><creatorcontrib>Wu, Shuai</creatorcontrib><creatorcontrib>Zhu, Changxin</creatorcontrib><creatorcontrib>Wang, Xiaoyan</creatorcontrib><title>Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background and Aims
Crohn’s disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD.
Methods
Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform.
Results
Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258,
p
< 0.05) and Shannon diversity index (2.05 vs. 3.46,
p
< 0.05). The CD patients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CD patients had lower levels of
Bacteroides
,
Eubacterium
,
faecalibacterium
, and
Roseburia
, and higher levels of
Clostridium
,
Cronobacter
,
Fusobacterium
, and
Streptococcus
.
Conclusions
FMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CD patients.</description><subject>Biochemistry</subject><subject>Colonoscopy</subject><subject>Crohn's disease</subject><subject>Feces</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Microbiota</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Transplant Surgery</subject><subject>Transplants & implants</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kcFu1DAURSMEokPhB1ggS2zYpPjZiZ2wq6YtVCqwYFhbjvM84yqxBzupNBILfoPf40vwdEoRCCEvbNnnXt-nWxTPgZ4ApfJ1AioYLSm0Ja1lDeXuQbGAWvKS1aJ5WCwoiHwGEEfFk5SuKaWtBPG4OOLAhWykXBRfL9Dogbx3JobOhUmTVdQ-bQftJ3LjNDn3fUgmbJ0hZzi4G4zOr8lqE8O83pBPox4GcuknTJPzSLTvyTIMwb8hHwI5c9ZiRG-Q2BDJMoaN__Hte8oPCXXCp8Ujq4eEz-724-Lzxflq-a68-vj2cnl6VZqqYlMJ0La2Zb3omZWdAMYENVa3TQeMy471FjmApqIREuseGXAOdVf3lZRG9sCPi1cH320MX-YcVY0uGRzykBjmpLKhlFXDG57Rl3-h12GOPqe7pVhT1xm8p9Z6QOW8DVPUZm-qTiWwltdVtf_25B9UXj2OzgSP1uX7PwTsIMhlpBTRqm10o447BVTtK1eHylWuXN1WrnZZ9OIu8dyN2N9LfnWcAX4A0nbfHcbfI_3H9ifnhbYe</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Yang, Zhenyu</creator><creator>Bu, Chibin</creator><creator>Yuan, Wei</creator><creator>Shen, Zhaohua</creator><creator>Quan, Yongsheng</creator><creator>Wu, Shuai</creator><creator>Zhu, Changxin</creator><creator>Wang, Xiaoyan</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2020</creationdate><title>Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease</title><author>Yang, Zhenyu ; Bu, Chibin ; Yuan, Wei ; Shen, Zhaohua ; Quan, Yongsheng ; Wu, Shuai ; Zhu, Changxin ; Wang, Xiaoyan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-1199f92d6d2f7b612260cfa98b1237b2dfe311a06867e5de213315b5d477c7d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biochemistry</topic><topic>Colonoscopy</topic><topic>Crohn's disease</topic><topic>Feces</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Microbiota</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Transplant Surgery</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Zhenyu</creatorcontrib><creatorcontrib>Bu, Chibin</creatorcontrib><creatorcontrib>Yuan, Wei</creatorcontrib><creatorcontrib>Shen, Zhaohua</creatorcontrib><creatorcontrib>Quan, Yongsheng</creatorcontrib><creatorcontrib>Wu, Shuai</creatorcontrib><creatorcontrib>Zhu, Changxin</creatorcontrib><creatorcontrib>Wang, Xiaoyan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Zhenyu</au><au>Bu, Chibin</au><au>Yuan, Wei</au><au>Shen, Zhaohua</au><au>Quan, Yongsheng</au><au>Wu, Shuai</au><au>Zhu, Changxin</au><au>Wang, Xiaoyan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2020</date><risdate>2020</risdate><volume>65</volume><issue>1</issue><spage>150</spage><epage>157</epage><pages>150-157</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background and Aims
Crohn’s disease (CD) is a chronic inflammatory bowel disorder associated with intestinal dysbiosis. This study aimed to determine the efficacy and safety of different methods of fecal microbiota transplantation (FMT), a potential therapy for CD.
Methods
Patients with CD were randomized to receive FMT by gastroscopy or colonoscopy; a second transplantation was performed 1 week later. Patients were assessed by clinical evaluation and serum testing (at weeks 1, 2, 4, 6, and 8) and endoscopy (8 weeks after transplantation). Fecal DNA was extracted and analyzed using the Illuminal sequencing platform.
Results
Of the 27 patients included in the study, clinical remission was achieved in 18 (66.7%); no significant difference was seen between the two methods. 76.9% of gastroscopy group patients and 64.3% of colonoscopy group patients experienced mild adverse events during or shortly after treatment. Microbiota diversity analyses showed that, in comparison with the donors, patients had lower operational taxonomic units (OTU; 117 vs. 258,
p
< 0.05) and Shannon diversity index (2.05 vs. 3.46,
p
< 0.05). The CD patients showed a significant increase in OTU and Shannon diversity index 2 weeks after FMT. In comparison with the donors, CD patients had lower levels of
Bacteroides
,
Eubacterium
,
faecalibacterium
, and
Roseburia
, and higher levels of
Clostridium
,
Cronobacter
,
Fusobacterium
, and
Streptococcus
.
Conclusions
FMT was seen to be safe and effective in this cohort of patients with CD. No significant differences in clinical remission rate and adverse events were seen between the gastroscopy and colonoscopy groups. FMT was seen to increase the species richness in CD patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>31367877</pmid><doi>10.1007/s10620-019-05751-y</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2020, Vol.65 (1), p.150-157 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A712935441 |
| source | Springer Online Journals |
| subjects | Biochemistry Colonoscopy Crohn's disease Feces Gastroenterology Hepatology Medical research Medicine Medicine & Public Health Medicine, Experimental Microbiota Microbiota (Symbiotic organisms) Oncology Original Article Transplant Surgery Transplants & implants |
| title | Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn’s Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A50%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fecal%20Microbiota%20Transplant%20via%20Endoscopic%20Delivering%20Through%20Small%20Intestine%20and%20Colon:%20No%20Difference%20for%20Crohn%E2%80%99s%20Disease&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Yang,%20Zhenyu&rft.date=2020&rft.volume=65&rft.issue=1&rft.spage=150&rft.epage=157&rft.pages=150-157&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-019-05751-y&rft_dat=%3Cgale_proqu%3EA712935441%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2267285548&rft_id=info:pmid/31367877&rft_galeid=A712935441&rfr_iscdi=true |